v3.26.1
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
OPERATING ACTIVITIES:    
Net loss $ (15,115) $ (13,543)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 679 1,760
Gain on sale of Orthobiologics Business (425)  
(Gain) loss on revaluation of warrant liability 1,429 (7,420)
Amortization of deferred financing costs and debt discount   107
Interest expense recorded as additional revenue interest obligation or long-term debt 285 2,646
Stock-based compensation 1,836 2,360
Changes in right-of-use assets and lease liabilities and lease incentives received 408  
Payments on revenue interest obligation (1,100)  
Changes in operating assets and liabilities:    
Accounts receivable 296 (874)
Inventory (32) (1,332)
Insurance receivables of litigation costs 994 463
Prepaid expenses and other 892 1,153
Accounts payable and accrued expenses (816) 1,021
Contingent liability for legal proceedings (5,623) (3,417)
Other liabilities   (33)
Net cash used in operating activities (16,292) (17,109)
INVESTING ACTIVITIES:    
Proceeds from sale of Orthobiologics Business 425  
Expenditures for property and equipment (550) (392)
Net cash used in investing activities (125) (392)
FINANCING ACTIVITIES:    
Proceeds from private placement and warrants, net of offering costs   13,796
Repayments of insurance premium financings   (865)
Payments for taxes upon vesting of restricted stock units (86) (249)
Proceeds from stock option exercises and issuance common stock under ESPP 49 80
Net cash provided by (used in) financing activities (37) 12,762
Net (decrease) increase in cash and cash equivalents (16,454) (4,739)
Cash and cash equivalents, beginning of period 36,350 13,239
Cash and cash equivalents, end of period 19,896 8,500
Supplemental Cash Flow and Non-Cash Financing Activities Disclosures:    
Cash paid for interest 1,100 548
Issuance of common stock as payment under revenue interest obligation   2,200
Conversion of Prefunded Warrants to common stock 1,390 890
Operating lease right-of-use asset extensions executed, net of early terminations $ 113 $ 2,271